Sigma Planning Corp increased its position in shares of Edwards Lifesciences Corp. (NYSE:EW) by 1.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,609 shares of the medical research company’s stock after buying an additional 31 shares during the period. Sigma Planning Corp’s holdings in Edwards Lifesciences Corp. were worth $260,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Checchi Capital Advisers LLC boosted its stake in shares of Edwards Lifesciences Corp. by 3.9% in the second quarter. Checchi Capital Advisers LLC now owns 2,039 shares of the medical research company’s stock valued at $203,000 after buying an additional 76 shares in the last quarter. Duncker Streett & Co. Inc. boosted its stake in Edwards Lifesciences Corp. by 10.5% in the second quarter. Duncker Streett & Co. Inc. now owns 1,264 shares of the medical research company’s stock valued at $126,000 after buying an additional 120 shares during the period. Advisor Partners LLC boosted its stake in Edwards Lifesciences Corp. by 4.3% in the first quarter. Advisor Partners LLC now owns 3,953 shares of the medical research company’s stock valued at $349,000 after buying an additional 162 shares during the period. Hills Bank & Trust Co. boosted its stake in Edwards Lifesciences Corp. by 6.8% in the first quarter. Hills Bank & Trust Co. now owns 3,160 shares of the medical research company’s stock valued at $279,000 after buying an additional 200 shares during the period. Finally, Bayesian Capital Management LP boosted its stake in Edwards Lifesciences Corp. by 4.4% in the first quarter. Bayesian Capital Management LP now owns 6,390 shares of the medical research company’s stock valued at $564,000 after buying an additional 272 shares during the period. 85.21% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Corp. (NYSE:EW) traded down 0.32% during trading on Friday, reaching $116.60. 1,476,041 shares of the company traded hands. The firm has a market capitalization of $24.82 billion, a price-to-earnings ratio of 48.18 and a beta of 0.60. The company’s 50-day moving average price is $114.60 and its 200 day moving average price is $103.38. Edwards Lifesciences Corp. has a 52 week low of $66.57 and a 52 week high of $118.92.

Edwards Lifesciences Corp. (NYSE:EW) last released its quarterly earnings results on Tuesday, July 26th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.06. The business had revenue of $759.30 million for the quarter, compared to analysts’ expectations of $724.26 million. Edwards Lifesciences Corp. had a net margin of 19.26% and a return on equity of 23.72%. The firm’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.57 earnings per share. On average, equities research analysts expect that Edwards Lifesciences Corp. will post $2.88 EPS for the current year.

EW has been the topic of several analyst reports. Credit Suisse Group AG restated a “buy” rating on shares of Edwards Lifesciences Corp. in a report on Wednesday, June 8th. Canaccord Genuity restated a “buy” rating and issued a $132.00 price objective on shares of Edwards Lifesciences Corp. in a report on Wednesday, June 1st. JPMorgan Chase & Co. restated a “buy” rating on shares of Edwards Lifesciences Corp. in a report on Tuesday, July 12th. Bank of America Corp. upgraded shares of Edwards Lifesciences Corp. from a “neutral” rating to a “buy” rating and set a $130.00 price objective on the stock in a report on Wednesday, July 27th. Finally, BTIG Research increased their price objective on shares of Edwards Lifesciences Corp. from $122.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $118.13.

In other Edwards Lifesciences Corp. news, CEO Michael A. Mussallem sold 49,100 shares of the firm’s stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $113.31, for a total transaction of $5,563,521.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Schack Wesley W. Von sold 6,000 shares of the firm’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $113.98, for a total value of $683,880.00. The disclosure for this sale can be found here. 2.37% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Corp. Company Profile

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp. (NYSE:EW).

Receive News & Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.